Copyright © 2019. Inderes Oy. All rights reserved.
Nexstim
3136 investors follow this company
The company is not covered. See all listed companies from here.
BUY 0.05 LOWEST 0.05 VOLUME 4 136 726
SELL 0.05 HIGHEST 0.06 VALUE 0,222 Milj. EUR

Would you like to see our recommendations and target prices?

You already have an Inderes account? Log in from here.

Analyst

Latest insider trading

Net impact profile

Stock release
27.10.
2020

Press Release, Helsinki, 27 October 2020 at 12.00 pm (EET)

Nexstim Has Received Three NBS System Orders in Europe

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has received three NBS System orders in Europe in October.

Stock release
14.10.
2020

Press release, Helsinki, 14 October 2020 at 10.00 (EEST)

Nexstim Podium Webinars Demonstrate How Nexstim Systems Have Advanced the Standard of Care for Patients

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that the Nexstim Podium live webinar series, launched this spring, has successfully gathered large audiences to discuss how nTMS has been advancing the standard of care for patients worldwide.

Stock release
5.10.
2020

Press Release, Helsinki, 5 October 2020 at 13.30 (EEST)

Nexstim Continues to Report Promising Results in Quickly Growing Number of Patients Completing SmartFocus® rTMS Treatment of Major Depressive Disorder

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") reports very promising clinical outcomes of the 108 patients who have completed Nexstim SmartFocus® rTMS treatment with Nexstim NBT® system for major depressive disorder (MDD).

Stock release
25.9.
2020

Company Announcement, Inside Information, Helsinki, 25 September 2020 at 9.50 am (EEST)

Pilot Study for New Chronic Pain Treatment Protocol with Nexstim NBT® System Starts in Helsinki University Hospital

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that a pilot study on the use of accelerated iTBS protocol in treatment of therapy resistant, chronic neuropathic pain with Nexstim NBT® System is starting at Helsinki University Hospital.

Stock release
22.9.
2020

Company Announcement, Inside information, Helsinki, 22 September 2020 at 9.30 am (EEST)

Pilot Study for New Depression Treatment Protocol with Nexstim NBT® System Starts in Kuopio University Hospital

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that a pilot study on the use of  accelerated iTBS protocol in treatment of severe depression with Nexstim NBT® System is starting at Kuopio University Hospital.

Stock release
16.9.
2020

Press Release, Helsinki, 16 September 2020 at 13.00 (EEST)

Nexstim Has Received Two NBS System Upgrade Orders in the United States

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has in September received two new NBS System upgrade orders from two large hospitals in the United States.

System upgrade means upgrading the hospital’s existing Nexstim NBS system technology to the latest SmartFocus® nTMS features that will replace the older system platform.

Stock release
14.9.
2020

Company announcement, inside information, Helsinki, 14 September 2020 at 14.30 (EEST)

Nexstim Plc: Change in the composition of the Shareholders’ Nomination Committee

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “the Company”) is announcing a change in the composition of the Shareholders’ Nomination Committee.

Stock release
10.9.
2020

Press Release, Helsinki, 10 September 2020 at 11.00 am (EEST)

Nexstim Pre-Surgical Mapping Technology Covered in over 100 Scientific Articles

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that the number of scientific articles covering patients undergoing pre-operative mapping with Nexstim’s NBS System prior to neurosurgery has exceeded 100.

Stock release
4.9.
2020

Press Release, Helsinki, 4 September 2020 at 9.30 am (EEST)

BrainStim Centers orders a second Nexstim NBT® System with SmartFocus® TMS

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that BrainStim Centers, US  has ordered a second Nexstim NBT® System with SmartFocus® TMS technology.

Stock release
27.8.
2020

Press release, Helsinki, 27 August 2020 at 14.30 (EEST)

Nexstim NBT® System with SmartFocus® TMS sold to Neurological Institute of Los Angeles

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that Neurological Institute of Los Angeles has purchased a Nexstim NBT® System with SmartFocus® TMS.

Nexstim

English translation unavailable for Nexstim.
Nexstim lyhyesti